GlassScriptPhysician profile
Corrie Henry
NPI 1306801253
$9,354.52
in general payments reported to CMS, 2019-2025
21 companies · $544 in 2025
The $544 reported for 2025 was more than what 86% of Obstetrics & Gynecology (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Obstetrics & Gynecology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $7,823 · 2022: $429 · 2023: $306 · 2024: $252 · 2025: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,102.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,459.00 | 2021-2025 | |
| Pfizer INC. | $1,080.00 | 2021 | |
| Mayne Pharma Commercial LLC | $360.41 | 2022-2025 | |
| Evofem Biosciences, INC. | $238.03 | 2021-2022 | |
| Myovant Sciences INC. | $237.72 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $178.34 | 2021-2025 | |
| Astellas Pharma US INC | $161.90 | 2023-2024 | Veozah |
| Biogen, INC. | $117.89 | 2025 | Zurzuvae |
| Millicent US INC | $89.61 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Sumitomo Pharma America, INC. | $69.48 | 2023-2025 | Myfembree |
| Exact Sciences Corporation | $68.38 | 2023-2025 | Cologuard Collection Kit |
| Coopersurgical, INC. | $62.77 | 2021-2024 | Paragard T 380a |
| Hologic Sales and Service, LLC | $62.31 | 2023-2025 | Thinprep 2000 Processor, Aptima, Myosure Tissue Removal Device |
| Avion Pharmaceuticals | $38.18 | 2021-2022 | |
| Novo Nordisk INC | $26.67 | 2023 | Wegovy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $20.60 | 2021 | |
| Mylan Pharmaceuticals INC. | $19.47 | 2021 | |
| Lupin INC. | $19.01 | 2021 | |
| Agile Therapeutics, INC. | $17.24 | 2021 | |
| Amgen INC. | $15.98 | 2023 | Prolia, Evenity |
| Glaxosmithkline, LLC. | $11.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corrie Henry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.